Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a zap on the forehead ease Parkinson's shuffling?

NCT ID NCT07656129

Symptom relief Sponsor: Zhengli Di Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive device that gently stimulates a nerve on the forehead (external trigeminal nerve stimulation, or eTNS) can immediately improve walking and other movement problems in people with Parkinson's disease. Thirty participants will each try two different stimulation frequencies and a sham (fake) session in random order, all while on their regular medication. The goal is to see if eTNS can reduce the difficulty of walking while doing another task, like talking.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
external trigeminal nerve stimulation (eTNS) device
What this could lead to
If it works, this could point toward a non-invasive, drug-free way to temporarily improve walking and movement in people with Parkinson's disease.
What could go wrong
This is a very small, early study (30 people) testing only immediate effects in a single session. It may not show meaningful improvement or translate to long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with idiopathic Parkinson's disease diagnosed by two neurologists, according to the Chinese diagnostic criteria for Parkinson's disease formulated in 2020 by the Chinese Parkinson's Disease and Movement Disorders Society based on the MDS Clinical Diagnostic Criteria for Parkinson's disease. 2. Hoehn and Yahr stage 1-5 in the medication ON state. 3. Mini-Mental State Examination (MMSE) score \>24. 4. Stable antiparkinsonian medication for at least 1 month before the trial. 5. No history of orthopedic or musculoskeletal disorders, and no other conditions that may affect balance or gait, such as ophthalmologic disorders. 6. No history of epilepsy, intracranial tumors, or other neurological disorders; no severe psychiatric disorders, such as schizophrenia; and no long-term use of antipsychotic medications. 7. Age between 40 and 80 years. 8. Ability to cooperate with all assessments and eTNS treatment, and provision of written informed consent. Exclusion Criteria: 1. Secondary parkinsonism or atypical parkinsonian syndromes. 2. Current use of anticholinergic medications. 3. Contraindications to non-invasive electrical neuromodulation. 4. Previous eTNS treatment within the past 6 months. 5. Severe neurological, renal, cardiovascular, hepatic, or other major systemic diseases. 6. Inability to complete clinical assessments or refusal to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neurologic Manifestations Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xi'an Central Hospital, Department of Neurology

    Xi'an, Shaanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.